Concordia Healthcare Corp. announces filing of Ulesfia® with Health Canada

December 30, 2013


TORONTO, Dec. 30, 2013 /PRNewswire/ – Concordia Healthcare Corp., an integrated, specialty healthcare company focused on the acquisition
of legacy pharmaceutical products, the acquisition and development of
orphan drugs, and distribution of medical devices servicing the
diabetic population announced today that it has filed a submission with
Health Canada for approval to market Ulesfia® in Canada.

“The filing of Ulesfia® with Health Canada begins the expansion of our
products into other geographic regions,” said Mark Thompson, chief
executive officer of Concordia. “The filing begins the 180 day review
process and during that time we will look for a partner to promote
Ulesfia® in Canada.” Ulesfia® (benzyl alcohol) Lotion is a prescription
non-pesticide Head Lice Treatment currently sold in the United States.

About Concordia

Concordia Healthcare is a diverse healthcare company focused on legacy
pharmaceutical products, orphan drugs and medical devices for the
diabetic population

The company’s legacy pharmaceutical business consists of an
ADHD-treatment drug, Kapvay® (clonidine extended release tablets),
Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an
Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate
orally disintegrating tablets). Concordia’s Specialty Healthcare
Distribution (SHD) division (Complete Medical Homecare) was acquired in
October, 2013 and Concordia’s orphan division, Pinnacle Biologics Inc., was acquired in December of 2013. Kapvay® and
Orapred ODT® are not authorized for sale in Canada.

Concordia operates out of facilities in Oakville, Ontario, Lenexa,
Kansas (near Kansas City, Missouri), Chicago, Illinois and Bridgetown,

Notice regarding forward-looking statements:

This release includes forward-looking statements regarding Concordia
Healthcare Corp. and its business. Often, but not always,
forward-looking statements can be identified by the use of words such
as “plans”, “is expected”, “expects”, “scheduled”, “intends”,
“contemplates”, “anticipates”, “believes”, “proposes” or variations
(including negative variations) of such words and phrases, or state
that certain actions, events or results “may”, “could”, “would”,
“might” or “will” be taken, occur or be achieved. Such statements are
based on the current expectations of Concordia’s management. The
forward-looking events and circumstances discussed in this release may
not occur by certain specified dates or at all and could differ
materially as a result of known and unknown risk factors and
uncertainties affecting the company, including risks regarding the
pharmaceutical industry, the ability to expand Concordia’s products
into other geographic regions, the receipt of approval to market
Concordia’s products in certain markets, including Canada, the ability
to locate partners to promote Concordia’s products in Canada, the
further development of Concordia’s products, the growth of Concordia,
failure to obtain regulatory approvals, economic factors, the equity
markets generally and many other factors beyond the control of
Concordia. Although Concordia has attempted to identify important
factors that could cause actual actions, events or results to differ
materially from those described in forward-looking statements, there
may be other factors that cause actions, events or results to differ
from those anticipated, estimated or intended. No forward-looking
statement can be guaranteed. Except as required by applicable
securities laws, forward-looking statements speak only as of the date
on which they are made and Concordia undertakes no obligation to
publicly update or revise any forward-looking statement, whether as a
result of new information, future events, or otherwise.

SOURCE Concordia Healthcare Corp.

Source: PR Newswire

comments powered by Disqus